Cannabidiol administered during peri-adolescence prevents behavioral abnormalities in an animal model of schizophrenia (2018)
- Authors:
- USP affiliated authors: ZUARDI, ANTONIO WALDO - FMRP ; HALLAK, JAIME EDUARDO CECILIO - FMRP ; CRIPPA, JOSÉ ALEXANDRE DE SOUZA - FMRP
- Unidade: FMRP
- DOI: 10.3389/fphar.2018.00901
- Subjects: CANABINOIDES; ESQUIZOFRENIA; SEROTONINA; MODELOS ANIMAIS DE DOENÇAS
- Keywords: Schizophrenia; Cannabidiol; SHR strain; Prevention; Side effects; Animal models; Serotonin; BDNF
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Frontiers in Pharmacology
- ISSN: 1663-9812
- Volume/Número/Paginação/Ano: v. 9, art. 901, 2018
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by
-
ABNT
PERES, Fernanda Fiel et al. Cannabidiol administered during peri-adolescence prevents behavioral abnormalities in an animal model of schizophrenia. Frontiers in Pharmacology, v. 9, 2018Tradução . . Disponível em: https://doi.org/10.3389/fphar.2018.00901. Acesso em: 05 ago. 2024. -
APA
Peres, F. F., Diana, M. C., Levin, R., Suiama, M. A., Almeida, V., Vendramini, A. M., et al. (2018). Cannabidiol administered during peri-adolescence prevents behavioral abnormalities in an animal model of schizophrenia. Frontiers in Pharmacology, 9. doi:10.3389/fphar.2018.00901 -
NLM
Peres FF, Diana MC, Levin R, Suiama MA, Almeida V, Vendramini AM, Santos CM, Zuardi AW, Hallak JEC, Crippa JA de S, Abilio VC. Cannabidiol administered during peri-adolescence prevents behavioral abnormalities in an animal model of schizophrenia [Internet]. Frontiers in Pharmacology. 2018 ; 9[citado 2024 ago. 05 ] Available from: https://doi.org/10.3389/fphar.2018.00901 -
Vancouver
Peres FF, Diana MC, Levin R, Suiama MA, Almeida V, Vendramini AM, Santos CM, Zuardi AW, Hallak JEC, Crippa JA de S, Abilio VC. Cannabidiol administered during peri-adolescence prevents behavioral abnormalities in an animal model of schizophrenia [Internet]. Frontiers in Pharmacology. 2018 ; 9[citado 2024 ago. 05 ] Available from: https://doi.org/10.3389/fphar.2018.00901 - Cannabidiol: an anxiolytic or an antipsychotic new drug?
- Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizopherenia: an update
- Cannabidiol for the treatment of crack-cocaine craving: an exploratory double-blind study
- Acute harmine administration induces antidepressive-like effects and increases BDNF levels in the rat hippocampus
- Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders
- Administration of harmine and imipramine alters creatine kinase and mitochondrial respiratory chain activities in the rat brain
- Cannabidiol normalizes caspase 3, synaptophysin, and mitochondrial fission protein DNM1L expression levels in rats with brain iron overload: implication for neuroprotection
- Cannabidiol prevents motor and cognitive impairments induced by reserpine in rats
- Cannabinoid-based therapies and brain development: potential harmful effect of early modulation of the endocannabinoid system
- Cannabidiol and neuroprotection: evidence from preclinical studies
Informações sobre o DOI: 10.3389/fphar.2018.00901 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
